Potential reduction exposure products and FDA tobacco and regulation: a CNS call to action.

Janie Heath, Jeannette Andrews, Cindy R. Balkstra

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

A new generation of tobacco harm reduction products is stirring controversy and confusion among healthcare providers. These products, known as "potential reduction exposure products" (PREPs), can be described in terms of reported scientific evidence, as "the good, the bad, and the ugly." On the good side, there is sufficient scientific evidence to support the use of Commit, a new over-the-counter nicotine lozenge PREP, approved for smoking cessation. On the bad side, there is no scientific evidence to support the use of Ariva, another over-the-counter nicotine lozenge PREP, marketed as an alternative to cigarettes when smoking is restricted. On the ugly side, both of these PREPs are nicotine delivery systems with "candy-like" appearances; however, one (Commit) has the Food and Drug Administration (FDA) approval and the other (Ariva) does not. This article provides an overview of PREPs and strategies to help clinical nurse specialists (CNSs) address tobacco harm reduction issues.

Original languageEnglish
Pages (from-to)40-48
Number of pages9
JournalClinical Nurse Specialist
Volume18
Issue number1
StatePublished - Jan 2004

ASJC Scopus subject areas

  • Leadership and Management
  • Assessment and Diagnosis
  • Advanced and Specialized Nursing
  • LPN and LVN

Fingerprint

Dive into the research topics of 'Potential reduction exposure products and FDA tobacco and regulation: a CNS call to action.'. Together they form a unique fingerprint.

Cite this